Evidence map›Paper›PMID 36185206›Full record

ArticleFrontiers in oncology2022

Clinical features and prognostic factors in patients with microvascular infiltration of hepatocellular carcinoma: Development and validation of a nomogram and risk stratification based on the SEER database.

Dashuai Yang, Mingqiang Zhu, Xiangyun Xiong, Yang Su, Fangrui Zhao, Yong Hu, Guo Zhang, Junpeng Pei, Youming Ding

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dashuai YangDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Mingqiang ZhuDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Xiangyun XiongDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Yang SuDepartment of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology, Wuhan, China.
Fangrui ZhaoDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Yong HuDepartment of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China.
Guo ZhangDepartment of neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Junpeng PeiDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Youming DingDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The goal is to establish and validate an innovative prognostic risk stratification and nomogram in patients of hepatocellular carcinoma (HCC) with microvascular invasion (MVI) for predicting the cancer-specific survival (CSS). Methods: 1487 qualified patients were selected from the Surveillance, Epidemiology and End Results (SEER) database and randomly assigned to the training cohort and validation cohort in a ratio of 7:3. Concordance index (C-index), area under curve (AUC) and calibration plots were adopted to evaluate the discrimination and calibration of the nomogram. Decision curve analysis (DCA) was used to quantify the net benefit of the nomogram at different threshold probabilities and compare it to the American Joint Committee on Cancer (AJCC) tumor staging system. C-index, net reclassification index (NRI) and integrated discrimination improvement (IDI) were applied to evaluate the improvement of the new model over the AJCC tumor staging system. The new risk stratifications based on the nomogram and the AJCC tumor staging system were compared. Results: Eight prognostic factors were used to construct the nomogram for HCC patients with MVI. The C-index for the training and validation cohorts was 0.785 and 0.776 respectively. The AUC values were higher than 0.7 both in the training cohort and validation cohort. The calibration plots showed good consistency between the actual observation and the nomogram prediction. The IDI values of 1-, 3-, 5-year CSS in the training cohort were 0.17, 0.16, 0.15, and in the validation cohort were 0.17, 0.17, 0.17 ( Conclusions: A comprehensive risk stratification system and nomogram were established to forecast CSS for patients of HCC with MVI.

Indexed as

cancer-specific survivalhepatocellular carcinomamicrovascular invasionnomogramprognostic modelrisk stratification

Identifiers

PMID36185206
PMCPMC9515492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.